Background: End Stage Renal disease (ESRD) as it was historically termed is a term that encompasses all degrees of decreased renal function, from damaged-at risk through mild, moderate, and severe chronic kidney failure. ESRD is a worldwide public health problem. In the United States, there is a rising incidence and prevalence of kidney failure, with poor outcomes and high cost (see Epidemiology). Material and Methods: The blood sample for routine analysis (lipidogram) and specific analysis was taken at 08 o'clock in the morning with the room temperature that variated from 19 to 24°C, before the hemodialysis session, minimum 12 hours of fasting -with tendency to avoid the absorption effect of food by the intestine as well as avoid absorption of lipids and formation of chilomicrones. In all samples regardless of their group, the concentration of ApoC-II and lipids were analyzed in a period of 12 months in a period of 12 months (the measurements were made every three months, it means we totally made 3 measurements in 9 months). Results: The results from patients and controlling group for Apo-C3 and lipid profile (ChT, TG, HDL-ch, LDL-ch) are given in table number 3. A significant statistical difference with p<0.0001 is found from the results of the lipidic profile and ApoC-III of patients with ESRD treated with HD compared with the results of the controlling group for the same parameters. Conclusion: In this study patients with ESRD treated with HD have high parameters of ApoC-III, TG, LDL-ch but low concentrations of HDL-ch due to impaired catabolism of apolipoproteins in this specific group of patients. In all patients symptoms of CDV (myocardial infarction, angina pectoris, ischemia), acute coronary syndrome were noticed.
Introduction
Lipid metabolism disorders in patients with chronic terminal renal insufficiency were prescribed for first time in 1827 by Dr Bright, especially in the patients with nephrotic syndrome (10) . It is a known fact that patients with chronic renal terminal insufficiency (CTRI) present clinically with early atherosclerosis and serious cardio-vascular complications, cerebro-vascular and peripheral arterial injuries more frequently in very large number in younger population compared to the healthy population. Recently it has been verified that uremic hyperlipidemia persists in the early stages of kidney weakening, prior to treatment with hemodialysis (HD) and it is presented as basic factor of the beginning of atherogenic processes in patients with chronic terminal renal insufficiency. Determination of lipid and apolipoproteins profile in particular of their abnormalities in patients with chronic terminal renal insufficiency (CTRI) in the early stages of the disease, and analysis of ethiopathogenic mechanisms can significantly help in proposing preventive measures (dietary, treatment) with which there will be reduced visible frequent appearance of dyslipidemia, atherosclerotic lesions and reduced incidence of atherosclerosis in patients with CTRI randomized by gender and age (11) . Patients with terminal chronic renal failure (TCRF) mostly appear with the type IV type of secondary hyperlipoproteinemia (according to Frederickson's classification) where high concentrations of triglycerides dominates (hypetriglyceridemia values of 28-100%} (12, 13) . Apolipoprotein-C3 also known as apo-CIII is a protein that in humans is encoded by the Apo-C3 gene. Apo-CIII is a component of very low density lipopro-tein (VLDL). Apo-C3 is a relatively small protein containing 79 amino acids that can be glycosylated at threonine-74. The most abundant glycoforms are characterized by an Olinked disaccharide galactose linked to Nacetylgalactosamine (Gal-GalNAc), further modified with up to 2 sialic acid residues. Less abundant glycoforms are characterized by more complex and fucosylated glycanmoieties. Apolipoprotein C-III (apo-C3) is an 8.8 kDa glycolprotein synthesized by the liver and intestines. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to inhibit hepatic uptake of triglyceride-rich particles.The Apo-A1, Apo-C3 and Apo-A4 genes are closely linked in both rat and human genomes. The Apo-A-1 and Apo-A-4 genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hyper-triglyceridemia. Recent evidences suggest an intracellular role for Apo-C3 in promoting the assembly and secretion of triglyceride-rich VLDL particles from hepatic cells under lipid-rich conditions. However, two naturally occurring point mutations in human apo C3 coding sequence, namely Ala23Thr and Lys58Glu have been shown to abolish the intracellular assembly and secretion of triglyceriderich VLDL particles from hepatic cell. ApoC-III is highly associated with hypertriglyceridemia and is a powerful independent predictor of CVD risk in subjects without renal disease. In the circulation, apoC-III is associated with TRL and HDL exchanging rapidly between these lipoproteins. In vitro studies demonstrate that apoC-III inhibits LPL and HL activities and the uptake of TRL and their remnants by hepatic lipoprotein receptors (14, 15) . ApoC-III may also stimulate apoB and triglyceride synthesis and, hence, drive hepatic overpro-duction of VLDL particles. Elevated plasma apoC-III concentration, specifically its accumulation in TRL and their remnants, is a consistent feature of dyslipidemia in CKD (16, 17) . Of note, we recently reported that moderate CKD is associated with hypertriglyceridemia related to delayed catabolism of triglyceride-rich VLDL and IDL particles. In CKD subjects, plasma apoC-III concentration was significantly elevated and was an independent predictor of impaired VLDL catabolism (18, 19) . The underlying mechanism for the increased plasma apo-C3I concentration in these CKD subjects, however, has not been examined. A better understanding of the metabolism of apoC-III may clarify the association between dyslipidemia and CVD, with implications for better therapeutic management in the CKD population. In the present study, we investigated the kinetics of plasma apo-C3 in predialysis, moderate CKD subjects (defined as those with an estimated glomerular filtration rate [eGFR] of 30-60 ml/min). We hypothesized that subjects with moderate CKD would exhibit catabolic defects in apo-C3 metabolism. We also explored associations between the kinetics of plasma apo-C3 and VLDL apoB and other markers of TRL metabolism, including apoA-V.
Material and Methods
The blood sample for routine analysis (lipidogram) and specific analysis was taken at 08 o'clock in the morning with the room temperature that variated from 19 to 24°C, before the hemodialysis session, minimum 12 hours of fasting -with tendency to avoid the absorption effect of food by the intestine as well as avoid absorption of lipids and formation of hilomicrones.
In all samples regardless of their group, the concentration of ApoC-II and lipids were analyzed in a period of 12 months (the measurements were made every three months, it means we totally made 3 measurements in 9 months). In the study we had totally 240 subjects, 100 of them were treated with HD, 100 were healthy that served as a controlling group. From the patients treated with hemodialysis 45(45%) were females, 54 (55%) were male, the average age was 58.00 ±18.00, treated more than 12 years with hemodyalisis in Clinical Hospital of Tetovo. The controlling group consists 100 individuals 45 (45%) female and 55 (55%) male (table nr.1.) equal as the examined group in age, gender and nationality. In the cohort -prospective study (crosssection) total female participants were 100 (45%) the average age 59.60±12.80, 102 (55%) man with the average age of 58.70 14.60 (Table 1) .
Gender
Nr 
Results
The results from patients and controlling group for Apo-C3 and lipid profile (ChT, TG, HDL-ch, LDL-ch) are evidenced in table 3. Table 3 From the results of the lipidic profile and ApoC-III of patients with ESRD treated with HD and from the results of the controlling group for the same parameters it can be noticed a significant difference with p<0.0001. The difference between the value that was recorded average patients treated with dialysis in both sexes ( (25) reported that elevated plasma apoC-III concentrations, particularly the accumulation of apoC-III in VLDL particles, occur in moderate CKD (26) .
Examined parameters

ESRD
Compositional changes in apoB-containing lipoprotein may render these particles less suitable as substrates for hepatic receptor-mediated uptake (27) . Consistent with this notion, cellular studies report that apoC-III can abolish apoB-and apoEmediated binding of lipoproteins to the LDL receptor, either by masking or altering the conformation of apoB and apoE (28, 29) . Elevated apoC-III concentration in moderate CKD was primarily a function of impaired apoC-III fractional catabolism. Holdsworth et al. (30) showed that renal impairment was associated with excess sialylation of apoC-III, which may render apoC-IIIcontaining TRL particles less suitable as substrates for lipolytic degradation. Furthermore, the kidney is partly involved in the removal of apoC-III from plasma.
Decreased apoC-III fractional catabolism was associated with decreased VLDL particle catabolism in moderate CKD. The potential coupling of apoC-III and VLDL apoB metabolism is consistent with the role of apoC-III as a key regulator of apoB transport, as shown by recent studies using anti-apoC-III immu-noaffinity chromatography that demonstrates kinetic and structural hetero-geneity of apoB-containing lipopro-teins, based on apoC-III content. Hence, the reduction in apoC-III fractional catabolism could partly be a consequence of moderate CKD. Pooled analysis of controls and CKD subjects showed a strong positive association between apoC-III catabolism and eGFR (r = 0.569, P< 0.0001). Similar associations were observed in CKD subjects but failed to reach statistical significance. In addition, protein carbamoylation and accumulation of advanced glycation end products in the setting of CKD have been shown to alter protein structure, enzymatic activities, and binding to cell surface receptors. Hence, modification of apoC-III structure and binding could contribute to altered apoC-III catabolism in CKD (31, 32) . Elevated apoC-III concentra-tion is a common feature of dyslipidemia in CKD subjects. In addition, it is increasingly recognized as an important risk factor for CVD in the general population and may be an important target in CKD subjects. 
Conclusion
In this study patients with ESRD treated with HD have high parameters of ApoC-III,TG,LDL-ch but low concentrations of HDL-ch approve for impaired catabolism of apolipoproteins in this specific group of patients. In all patients we had symptoms of CDV(myocardial infarction, angina pectoris, ischemia), acute coronary syndro-me.Most common dislipidemy was hipertri-gliceri-demy 90.0-95.0%) in samples with ESRDI treated with HDallow necessarily should be treated with fibrate, bezafibrate, clofibrate not with statine. Concentrations of ApoC-III in the examined group were 5-6 times higher compared to the controlling group. The role and clinical examination of apolipo-protein means early diagnostification and preve-ntion of visceral and peripheral atheroscle-rosis as accelerator for cardio/neuro vascular diseases. Determination of apolipoproteinic and lipidic concentrations enables preven-tive measurements for avoiding at least on etiopatho-logical factor for accelerate atherosclerosis. That's why we can conclude that exami-nation and treatment of apolipoproteine in the early stages of the diseases should be the first postulate in the treat-ment of CKD patients, this approach to the disease significantly will reduce the risk for CDV. Hypertrigliceridemy in uremic patients treated with HD is associated with genetic variations.
